Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Drug development costs when financial risk is measured using the Fama–French three‐factor model

5 references·5 citing·30 second hop

FromToDepth

this work references cited by second hop

References

1993Common risk factors in the returns on stocks and bonds26,615 cited
2001The theory and practice of corporate finance: evidence from the field5,947 cited
2003The price of innovation: new estimates of drug development costs4,264 cited
2002Returns on Research and Development for 1990s New Drug Introductions311 cited
1995A CEO Survey of U.S. Companies' Time Horizons and Hurdle Rates258 cited

Cited by

2013Market spiral pricing of cancer drugs92 cited
2021R&D Costs of New Medicines: A Landscape Analysis87 cited
2014Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs75 cited
2014Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders73 cited
2012Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms33 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work